Evaluation of targeted arterial delivery of the branched chain fatty acid 12-methyltetradecanoic acid as a novel therapy for solid tumors

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 1, 2005, Pages 55-68

  Wright, Kenneth C ^a   Yang, Peiying ^a   Van Pelt, Carolyn S ^a   Hicks, Marshall E ^a   Collin, Peter ^b   Newman, Robert A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Coastside Research ^*  (United States)

Author keywords

12 methyltetradecanoic acid; Branched chain fatty acids; Rabbits; Targeted arterial delivery; VX2 carcinoma

Indexed keywords

12 METHYLTETRADECANOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; CASPASE 3; CYCLOOXYGENASE 2; DRUG METABOLITE; ETHIODIZED OIL; FATTY ACID DERIVATIVE; ICOSANOID; LIPOXYGENASE; MYRISTIC ACID; PROSTAGLANDIN E2; SATURATED FATTY ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTERY CATHETER; ARTICLE; CANCER INHIBITION; CELL STRUCTURE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DEEP FEMORAL ARTERY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; EVALUATION; FLUOROSCOPY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INOCULATION; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; WESTERN BLOTTING;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ANIMALS; ANTINEOPLASTIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME INHIBITORS; FATTY ACIDS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; IMMUNOHISTOCHEMISTRY; NEOPLASM TRANSPLANTATION; NEOPLASMS; RABBITS; TISSUE FIXATION;

EID: 23044509081     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Cuendet M, Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metab Drug Interact 17:109-139, 2000.
2. Brash AR. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274:23679-23682, 1999.
3. Shureiqui I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 61:6307-6312, 2001.
4. de Leval X, Julemont F, Delarge J, Pirotte B, Dogne J-M. New trends in dual 5-LOX/COX inhibition. Curr Medicinal Chem 9:941-962, 2002.
5. Shimizu T, Izumi T, Seyama Y, Tadokoro K, Radmark O, Samuelsson B. Characterization of leukotriene A4 synthase from murine mast cells: Evidence for its identity to arachidonate 5-lipoxygenase. Proc Natl Acad Sci USA 83:4175-4179, 1986.
6. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1300:240-246, 1996.
7. Hussey HJ, Tisdale M. Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br J Cancer 70:6-10, 1994.
8. Hussey HJ, Tisdale MJ. Novel anti-tumor activity of 2,3,5-trimethyl-6-(3- pyridylmethyl)-1,4-benzoquinone (CV-6504) against established murine adenocarcinomas (MAC). Br J Cancer 73:1187-1192, 1996.
9. Anderson KM, Seed T, Vos M, Mulshine J, Meng J, Alrefai W, Ou D, Harris JE. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 37:161-173, 1998.
10. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: Critical role of 5-lipoxygenase. Biochem Biophys Res Commun 235:418-423, 1997.
11. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42:73-78, 2000.
12. Salido M, Vilches J, Lopez A, Roomans GM. X-ray microanalysis of etoposide-induced apoptosis in the PC3 prostate cancer cell line. Cell Biol Intern 25:499-508, 2001.
13. Yang P, Collin P, Madden T, Chan D, Sweeney-Gotsch B, McConkey, Newman RA. Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate 55:281-291, 2003.
14. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martinez A, Mulshine JL. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Investig 97:806-813, 1996.
15. Rioux N, Castonguay A. Inhibitors of lipoxygenase: A new class of cancer chemopreventive agents. Carcinogenesis (Lond.) 19:1393-1400, 1998.
16. Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 261:218-223, 1999.
17. Yang Z, Liu S, Chen X, Chen GH, Huang M, Zheng J. Induction of apoptotic cell death and in vivo growth inhibition of human cancer cells by a saturated branched-chain fatty acid, 13-methyltetradecanoic acid. Cancer Res 60:505-509, 2000.
18. Kempen EC, Yang P, Felix E, Madden T, Newman RA. Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem 297:183-190, 2001.
19. Yang P, Felix E, Madden T, Fischer SM, Newman RA. Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. Anal Biochem 308:168-177, 2002.
20. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK. Requirement of a 5-lipoxygenase-activating protein for Leukotriene synthesis. Nature (Lond.) 343:282-284, 1990.
21. Peters-Golden M. Cell biology of the 5-lipoxygenase pathway. Am J Respir Crit Care Med 157:5227-5231, 1998.
22. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91:737-743, 2001.
23. Collin P. Inventor; Coastside Research, Assignee. Marine carotenoid oils and methods of use. Australian patent 737,567,2001.
24. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 297:307-312, 1982.
25. Geschwind J-FH, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: Intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909-3913, 2002.
26. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 model for liver cancer. Cancer Lett 173:83-91, 2001.
27. Weisbroth SH. Neoplastic diseases. In: Weisbroth SH, Flatt RE, Kraus AL (eds) The Biology of the Laboratory Rabbit, Second Edition. New York: Academic Press, 1994, pg 281.
28. Iwai K, Maeda H, Konno T, Matsumura Y, Yamashita R, Yamasaki K, Hirayama S, Miyauchi Y. Tumor targeting by arterial administration of lipids: Rabbit model with VX2 carcinoma in the liver. Cancer Res 7:321-328, 1987.
29. Sheehan R, Hreshchyshyn M, Lin RK, Lessmann FP. The use of lymphography as a diagnostic method. Radiology 76:47-53, 1961.
30. Nakakuma K, Tashiro S, Uemura K. An attempt for increasing effects of hepatic artery ligation for advanced hepatoma. JapDeutsche Med Berichte 24:675-680, 1979.
31. Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and x-ray image. Cancer Res 44:2115-2121, 1984.
32. Nagamitsu A, Konno T, Oda T, Tabaru K, Ishimaru Y, Kitamural N. Targeted cancer chemotherapy for VX2 tumour implanted in the colon with Lipiodol as a carrier. Eur J Cancer 34:1764-1769, 1998.
33. Goldberg SN, Ahmed M. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Clin Gastroenterol 35:S115-S129, 2002.
34. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 13:5211-5221, 2002.
35. Solomon B, Soulen MC, Baum RA, Haskal ZJ, Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: Prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 10:793-798, 1999.
36. Gonzalez AL, Roberts RL, Massion PP, Olson SJ, Shyr Y, Shappell SB. 15-Lipoxygenase-2 expression in benign and neoplastic lung: An immunohistochemical study and correlation with tumor grade and proliferation. Hum Pathol 35:840-849, 2004.
37. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA Jr., Schappell SB. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: Correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31:1146-1154, 2000.
38. Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V, Iyengar S, Tang DG, Lippman SM. Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia (New York) 5:121-127, 2003.
39. Milas L, Stephens LC, Meyn RE. Relation of apoptosis to cancer therapy. In Vivo 8:665-674, 1994.
40. Wongtangtintharn S, Oku H, Iwasaki H and Toda T. Effect of branched chain fatty acid biosynthesis of human breast cancer cells. J. Nutr. Sci. Vitaminol. (Tokyo) 50:137-143, 2004.
41. 2 carcinoma cell growth in culture by calcium, calmodulin, and prostaglandins. Cancer Res 45:398-405, 1985.
42. Sheng, H, Shao J, Morrow JD, Beauchamp RD, Dubois RN. Modulation of apoptosis and Bcl-2 expression by protaglandin E2 in human colon cancer cells. Cancer Res 58:362-366, 1998.
43. Sheng, H, Shao J, Washington MK, Dubois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:18075-18081, 2001.
44. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptors: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Med 8:289-293, 2002.
45. Smith M-L, Chapple K, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: Evidence of different mechanisms of action (abstract). Gut 44(suppl 4):101A, 2000.
46. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908-7916, 1999.
47. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim KK. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a cyclooxygenase-2 inhibitor, NS-398. Clin Cancer Res 7:1410-1418, 2001.
48. Crew TE, Elder DJE, Paraskeva C. A cyclooxygenase-2 (COX-2) selective, non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: Regulation of COX-2 by butyrate. Carcinogenesis 21:69-77, 2000.